AbbVie clears new regulatory and M&A milestones, shares trade near fair value range
28.06.2026 - 14:56:58 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 14:56.
AbbVie Inc. (US00287Y1091) has lined up a cluster of regulatory wins and a major acquisition to reinforce its long-term growth story in the S&P 500 pharmaceutical space. The stock trades on the NYSE, where recent moves leave shares close to several fundamentally derived fair value marks, according to independent analysis.
New approvals and EU label expansions
On June 23, 2026, Allergan Aesthetics, AbbVie’s aesthetics arm, reported that Health Canada approved Boey for the temporary improvement of moderate to severe glabellar lines in adults, making it the first botulinum neurotoxin serotype E product with rapid onset and short duration in that indication.A detailed Yahoo Finance article on the Boey approval
In parallel, AbbVie announced that the European Commission approved Maviret, its oral pangenotypic direct-acting antiviral therapy, for treating acute hepatitis C virus infection in adults and children from 3 years of age. This decision makes Maviret the only therapy in the European Union cleared for both acute and chronic hepatitis C virus infection, widening its treatable patient pool compared with prior labeling.
Planned Apogee acquisition and long-term narrative
On June 22, 2026, AbbVie entered a definitive agreement to acquire Apogee Therapeutics in an all-cash deal that values the target’s equity at about 10.9 billion dollars, with AbbVie set to pay 135.11 dollars per Apogee share if the transaction closes as expected in fiscal Q3 2026.Transaction terms and strategic rationale reported by Yahoo Finance
Apogee brings multiple clinical-stage candidates across immunological and inflammatory diseases, including assets targeting asthma and atopic dermatitis, which AbbVie highlights as complementary to its current immunology franchise and as a way to strengthen its presence in respiratory indications over the coming decade.
Further news and figures on the AbbVie shares
For a broader view on AbbVie’s earnings path, dividend profile and analyst estimates, the ad-hoc-news topic page and AbbVie’s own Investor Relations site provide additional curated data.
The product and portfolio behind the stock
AbbVie’s core business spans immunology agents such as SKYRIZI and HUMIRA follow-on therapies, virology treatments including Maviret for hepatitis C, and an expanding aesthetics portfolio via Allergan Aesthetics, where Boey joins products like Botox and Juvederm as part of a diversified mix of cash-generative franchises in specialty pharmaceuticals.
Where the AbbVie stock trades today
AbbVie shares (US00287Y1091) most recently closed at 251.52 dollars on the NYSE on June 26, 2026, with after-hours indications around 252.95 dollars per share, according to consolidated price data.
Key data on the AbbVie shares
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- WKN: A1J84E
- Ticker: ABBV
- Trading venue: NYSE
- Price (as of 2026-06-26, 16:00): 251.52 USD
- Market cap: approximately 445 billion USD (as of 2026-06-26)
- Sector / industry: Pharmaceuticals & Biotechnology
- Index membership: S&P 500
- Next earnings date: 2026-07-31
Disclaimer: This text is for information only and does not contain investment advice, recommendations or solicitations to buy or sell securities. All data are based on sources cited in the article and may change without notice.
